Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

被引:103
作者
Kruczynski, A
Colpaert, F
Tarayre, JP
Mouillard, P
Fahy, J
Hill, BT
机构
[1] Ctr Rech Pierre Fabre, Div Expt Canc Res 1, F-81106 Castres 06, France
[2] Ctr Rech Pierre Fabre, Res Ctr Directorate, F-81106 Castres 06, France
[3] Ctr Rech Pierre Fabre, Div Med Chem 5, F-81106 Castres 06, France
关键词
vinflunine; murine tumors; human tumor xenografts; cancer chemotherapy;
D O I
10.1007/s002800050764
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vinflunine, or 20',20'-difluoro-3',4'-dihydrovinorelbine, is a novel Vinca alkaloid obtained by hemisynthesis using superacidic chemistry. The most impressive structural modification of this vinorelbine derivative was the selective introduction of two fluorine atoms at the 20' position, a part of the molecule previously inaccessible by classic chemistry. The antitumor activity of vinflunine was evaluated against a range of transplantable murine and human tumors. Vinflunine exhibited marked activity against murine P388 leukemia grafted i.v. when given i.p. in single or multiple doses according to various schedules or in single i.v. or p.o. doses. Increases in life span achieved with vinflunine, as assessed by T/C ratios, ranged from 200% to 457% and proved markedly superior to those of 129-186% obtained with the other Vinca alkaloids tested. Against s.c.-implanted B16 melanoma, multiple i.p. administration of vinflunine proved active in terms of both survival prolongation and tumor growth inhibition, with optimal T/C values and relative areas under the tumor growth curves (rAUC) being 24% and 36%, respectively. The extent of this activity was superior to that noted for vinorelbine under the same experimental conditions. Growth inhibition of human tumor xenografts LX-1 (lung) and MX-1 (breast) was also observed following four weekly i.p. injections of vinflunine as reflected by optimal T/C values of 23% and 26%, respectively, and significant differences in the rAUCs noted for treated versus control animals. It was also noticeable that vinflunine induced considerably more prolonged inhibitory effects on tumor growth than did vinorelbine. These results demonstrate that vinflunine is well tolerated and is definitively active against a range of experimental animal tumor models. Vinflunine activity has been documented in terms of both survival prolongation and tumor growth inhibition, with definite superiority over vinorelbine being shown in each tumor model evaluated.
引用
收藏
页码:437 / 447
页数:11
相关论文
共 37 条
[11]   RESPONSE OF HUMAN TUMOR XENOGRAFTS IN ATHYMIC NUDE-MICE TO DOCETAXEL (RP-56976, TAXOTERE(R)) [J].
DYKES, DJ ;
BISSERY, MC ;
HARRISON, SD ;
WAUD, WR .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (01) :1-11
[12]  
Fahy J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P226
[13]  
FIEBIG HH, 1992, CONTR ONCOL, V42, P321
[14]   VINORELBINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL USE IN CANCER-CHEMOTHERAPY [J].
GOA, KL ;
FAULDS, D .
DRUGS & AGING, 1994, 5 (03) :200-234
[15]   KINETIC-ANALYSIS OF COMBINATION EFFECT OF NAVELBINE (KW-2307) WITH CISPLATIN AGAINST HUMAN LUNG ADENOCARCINOMA PC-12 CELLS IN CULTURE [J].
GOMI, K ;
OHNO, H ;
NOMURA, K ;
OKABE, M ;
KOBAYASHI, K ;
NIITANI, H .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (05) :532-539
[16]   COMPARATIVE ANTITUMOR-ACTIVITY OF VINBLASTINE-ISOLEUCINATE AND RELATED VINCA ALKALOIDS IN HUMAN TUMOR XENOGRAFTS [J].
HENDRIKS, HR ;
LANGDON, S ;
BERGER, DP ;
BREISTOL, K ;
FIEBIG, HH ;
FODSTAD, O ;
SCHWARTSMANN, G .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :767-773
[17]  
JOHNSON IS, 1963, CANCER RES, V23, P1390
[18]  
JOHNSON IS, 1959, J LAB CLIN MED, V54, P830
[19]   Vinorelbine: An overview [J].
Johnson, SA ;
Harper, P ;
Hortobagyi, GN ;
Pouillart, P .
CANCER TREATMENT REVIEWS, 1996, 22 (02) :127-142
[20]   INHIBITION OF FARNESYLTRANSFERASE INDUCES REGRESSION OF MAMMARY AND SALIVARY CARCINOMAS IN RAS TRANSGENIC MICE [J].
KOHL, NE ;
OMER, CA ;
CONNER, MW ;
ANTHONY, NJ ;
DAVIDE, JP ;
DESOLMS, SJ ;
GIULIANI, EA ;
GOMEZ, RP ;
GRAHAM, SL ;
HAMILTON, K ;
HANDT, LK ;
HARTMAN, GD ;
KOBLAN, KS ;
KRAL, AM ;
MILLER, PJ ;
MOSSER, SD ;
ONEILL, TJ ;
RANDS, E ;
SCHABER, MD ;
GIBBS, JB ;
OLIFF, A .
NATURE MEDICINE, 1995, 1 (08) :792-797